Comparative Pharmacology
Head-to-head clinical analysis: DEAPRIL ST versus LISINOPRIL AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEAPRIL ST versus LISINOPRIL AND HYDROCHLOROTHIAZIDE.
DEAPRIL-ST vs LISINOPRIL AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme (ACE) inhibitor. Inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure.
Lisinopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Oral: 2.5 mg twice daily, titrated up to 5 mg twice daily as tolerated. Maximum dose: 10 mg daily.
Initial dose: 10 mg/12.5 mg orally once daily. Titrate based on blood pressure response; maximum 40 mg/25 mg per day.
None Documented
None Documented
8-10 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Lisinopril: terminal half-life 12 hours, effective half-life ~30 hours due to prolonged ACE inhibition. Hydrochlorothiazide: terminal half-life 5.6-14.8 hours (mean 9.6 hours) in patients with normal renal function.
Renal (90% as unchanged drug), biliary/fecal (10%)
Lisinopril: primarily renal (100% unchanged in urine). Hydrochlorothiazide: renal (≥95% unchanged via tubular secretion).
Category C
Category D/X
ACE Inhibitor
ACE Inhibitor